Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $1.3 million.

  • Heron Therapeutics' Cash from Operations fell 6051.62% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.2 million, marking a year-over-year decrease of 26396.19%. This contributed to the annual value of -$22.5 million for FY2024, which is 6167.82% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Cash from Operations is $1.3 million, which was down 6051.62% from -$10.9 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Cash from Operations registered a high of $3.4 million during Q3 2024, and its lowest value of -$63.0 million during Q2 2021.
  • Moreover, its 5-year median value for Cash from Operations was -$24.9 million (2023), whereas its average is -$23.7 million.
  • The largest annual percentage gain for Heron Therapeutics' Cash from Operations in the last 5 years was 13672.51% (2024), contrasted with its biggest fall of 57983.71% (2024).
  • Heron Therapeutics' Cash from Operations (Quarter) stood at -$45.3 million in 2021, then increased by 17.07% to -$37.5 million in 2022, then soared by 106.54% to $2.5 million in 2023, then tumbled by 579.84% to -$11.8 million in 2024, then surged by 111.3% to $1.3 million in 2025.
  • Its Cash from Operations was $1.3 million in Q3 2025, compared to -$10.9 million in Q2 2025 and -$8.9 million in Q1 2025.